#USA #Scottsdale #Neurodegenerative Diseases #CND Life Sciences #Syn-One Test

CND Life Sciences Unveils a Revolutionary Diagnostic Tool for Neurodegenerative Diseases

In a significant advancement for medical diagnostics, CND Life Sciences, a pioneering medical technology company based in Scottsdale, Arizona, has recently published a promising study. This research, positioned in the Movement Disorders section of the journal Frontiers in Neurology, highlights the profound clinical utility of the Syn-One Test®, specifically designed to aid in the diagnosis of neurodegenerative diseases, particularly synucleinopathies like Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

Study Overview

The study encompasses a retrospective review of 97 patients suspected of having Parkinson's disease or related disorders. Key to this research was the Syn-One Test, which utilizes a skin biopsy to detect the abnormal accumulation of synuclein in cutaneous nerves. Remarkably, the findings indicated that over 75% of patients experienced alterations in clinical diagnosis or treatment based on the test results. More specifically, 78% of patients had their clinical management adjusted, and the study revealed that 66% experienced a diagnostic change, while 55% saw alterations in their treatment approach. This is particularly critical as neurodegenerative diseases often present diagnostic challenges that can lead to delays in appropriate patient care.

According to Todd Levine, MD, Chief Medical Officer of CND Life Sciences, neurologists have long necessitated an accurate diagnostic tool to facilitate the identification of such conditions. The Syn-One Test is a response to that need, aiding clinical practice and enhancing decision-making. Previous validation studies have established its reliability, further cementing its position as an essential diagnostic asset.

Clinical Implications

The potential impacts of neurodegenerative diseases are profound, often leading to extended periods of diagnostic uncertainty for patients. Dr. Jonathan Ross Isaacson, who led the study, emphasized the capabilities of the Syn-One Test in clarifying diagnoses and promoting referrals not only to neurologists but also to other relevant specialties. This broader cross-specialty collaboration could facilitate comprehensive care approaches involving neurosurgery, physical therapy, and occupational therapy, improving overall patient well-being.

With the observed shortage of specialists in movement and cognitive disorders, many patients currently lack timely access to appropriate care. The Syn-One Test's simplicity and efficacy allow it to be administered in routine office settings through a small punch biopsy, significantly benefiting patients across various geographical locations and at earlier stages of their diseases.

Supporting Evidence

This publication builds on earlier studies reflecting the test's capabilities, showcasing a collected body of evidence that bolsters the role of the Syn-One Test in clinical settings. Additionally, Dr. Roy Freeman, one of the authors, noted the importance of cutaneous detection of alpha-synuclein, which not only informs clinical decisions but also enhances patient care quality.

CND Life Sciences operates a CLIA-certified and CAP-accredited laboratory, dedicated to the advancement of diagnostic testing for neurodegenerative conditions. The Syn-One Test employs sophisticated immunofluorescence techniques for detecting phosphorylated alpha-synuclein, which indicate the presence of these diseases with over 95% sensitivity, as highlighted in a recent NIH-sponsored prospective study published in The Journal of the American Medical Association (JAMA).

Conclusion

As CND Life Sciences continues to innovate and expand its offerings, the Syn-One Test represents a critical advancement in the battle against neurodegenerative diseases. It not only streamlines the diagnostic process but also holds the potential for transforming patient care by providing timely and accurate assessments that guide treatment strategies. As they explore further applications and collaborations within the medical community, the future looks promising for improved outcomes in neurodegenerative disease management.

For further information about CND Life Sciences and the Syn-One Test, visit cndlifesciences.com.